InvestorsHub Logo

nidan7500

07/15/17 7:16 AM

#111328 RE: GrassyKnoll #111326

I made the mistake of asking how Homeostasis was measured in CNS context the other day, only to be told that.....YOO that is REAAALLY STUUPID question (my emphasis).

Eventually, if AVXL-Dr. M. is right about this, every clinic on the planet will be conducting these tests and all our current MRI/X-ray equipment will be used as sea anchors.

frrol

07/15/17 9:29 AM

#111338 RE: GrassyKnoll #111326

Yes, a lot of folks are exulting that "they said 2-73 restores cellular homeostasis!" but two points must be made:
This is theorized. We are trying to prove this.
Homeostasis in cells has MANY dimensions. We are just talking here about a couple dimensions that are relevant to some CNS pathologies.

TTTav66

07/15/17 9:46 AM

#111339 RE: GrassyKnoll #111326

Thanks for that, but I am aware that the term itself is not new. What I was looking into was the first time that Anavex used it to describe the potential MOA of 2-73.

I believe the first time it was described this way by Missling was in his excellent The Wall Street Transcript interview on October 21, 2016: https://seekingalpha.com/filing/3258966

He states it again in this podcast on November 9th around the 00:02:40 mark: https://player.fm/series/health-and-well-being/dr-christopher-missling-president-and-ceo-of-anavex

Interestingly on November 6th, this article had already picked up on the usage, putting their own spin on it here: https://insiderfinancial.com/anavex-life-sciences-corp-nasdaqavxl-is-changing-the-game-in-alzheimers/118101/

And, finally, as I stated in a previous post, the first time it made it into a PR looks to be on November 22, 2016 in the 41 week, pre-CTAD PR: http://www.anavex.com/anavex-life-sciences-announces-data-on-41-week-treatment-of-anavex-2-73-for-patients-with-alzheimers-disease/